GIMAP7 is a GTPase that functions as a homodimer with catalytic activity dependent on inter-subunit communication 1. The protein localizes to lipid droplets and the Golgi apparatus, where it regulates cellular processes including lymphocyte survival and immune homeostasis 1. GIMAP7 acts as a regulatory hub in multiple disease contexts: in lung adenocarcinoma, it suppresses proliferation, epithelial-mesenchymal transition, and glycolysis via the Smo/AMPK signaling pathway 2; in polycystic ovary syndrome, it promotes apoptosis and oxidative stress in granulosa cells by inhibiting sonic hedgehog signaling 3; and it complexes with GIMAP6 to regulate autophagy and immune competence 4. GIMAP7 expression is dysregulated across multiple conditions: downregulated in oral squamous cell carcinoma and acute myocardial infarction 56, while upregulated following anti-CD3 monoclonal antibody treatment in COVID-19, correlating with reduced effector T cell function 7. As an immune-associated GTPase, GIMAP7 represents a potential biomarker and therapeutic target in inflammatory, malignant, and infectious diseases.